, /PRNewswire/ -- ("P95"), an Ampersand Capital Partners portfolio company, is proud to announce the appointment of Laurence De Moerlooze as Chief Medical Officer (CMO). Laurence will provide medical leadership and spearhead operational oversight across P95's clinical and epidemiology activities, driving forward the company's strategic goals in vaccine innovation and public health. Laurence brings a wealth of expertise and leadership to P95's management team, shaped by an impressive career marked by pivotal positions such as Executive Vice President and Chief Medical Officer at Bavaria Nordic, and influential senior roles at Takeda and GSK.
After earning a PhD in Virology from the University of Liège and extensive post-doctoral work in , , and , Laurence amassed over 15 years at GSK Biologicals. During this time, she was at the forefront of regulatory affairs, project management, and medical affairs, playing a significant role in developing vaccines, including one for HPV. Her subsequent leadership extended to Zika and Norovirus vaccine development as a Vice President at Takeda, followed by her 4-year tenure as Chief Medical Officer at Bavarian Nordic.
Laurence's unique and vast understanding of vaccine development and implementation will be a tremendous asset to P95. , Chief Executive Officer of P95 expressed: " ." , an Ampersand portfolio company, is a leading global provider of clinical and epidemiology research solutions with a specialty focus on vaccines and infectious.
